Polyethylene glycol (PEG) modified bovine pericardium as a biomaterial: A comparative study on immunogenicity

被引:0
|
作者
Aravind, S [1 ]
Paul, W [1 ]
Vasudev, SC [1 ]
Sharma, CP [1 ]
机构
[1] Sree Chitra Tirunal Inst Med Sci & Technol, Biomed Technol Wing, Div Biosurface Technol, Trivandrum 695012, Kerala, India
关键词
D O I
暂无
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Bioprosthetic heart valves made from glutaraldehyde (GA)-fixed porcine aortic valves or bovine pericardium (BP) are having some advantages over mechanical valves. However, their durability is low due to the calcification and immunological rejection. Study on immunogenicity is an important part in understanding the biocompatibility of materials. Polyethylene glycol (PEG) on pericardium can control biodegradation and calcification. Also, PEG exhibits low immunogenicity. We have studied the complement activation potential and the contribution of complement factors (biologic factors) on the calcification of PEG grafted pericardium samples and compared with standard (control) glutaraldehyde-treated pericardium samples. PEG-grafted BP activated using GA and carbodiimide (EDC) could be selected for further studies since complement activation and calcification observed on these samples has been relatively low.
引用
收藏
页码:158 / 165
页数:8
相关论文
共 50 条
  • [21] Polyethylene glycol-grafted bovine pericardium: a novel hybrid tissue resistant to calcification
    S. C. VASUDEV
    T. CHANDY
    Journal of Materials Science: Materials in Medicine, 1999, 10 : 121 - 128
  • [22] Polylactic Acid (PLA) Modified by Polyethylene Glycol (PEG) for the Immobilization of Lipase
    Li, Shuhong
    Zhao, Shuang
    Hou, Yajie
    Chen, Guiyun
    Chen, Ye
    Zhang, Zhenya
    APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2020, 190 (03) : 982 - 996
  • [23] Polylactic Acid (PLA) Modified by Polyethylene Glycol (PEG) for the Immobilization of Lipase
    Shuhong Li
    Shuang Zhao
    Yajie Hou
    Guiyun Chen
    Ye Chen
    Zhenya Zhang
    Applied Biochemistry and Biotechnology, 2020, 190 : 982 - 996
  • [24] PREPARATION OF BOVINE LEUCOSIS VIRUS (BLV) ANTIGEN BY POLYETHYLENE-GLYCOL (PEG)
    FERENCZ, G
    VAJDA, B
    SIK, J
    HORVATH, Z
    MAGYAR ALLATORVOSOK LAPJA, 1982, 37 (10) : 663 - 667
  • [25] The physiological and histopathological response of dogs to exchange transfusion with polyethylene glycol-modified bovine hemoglobin (PEG-HB)
    Shum, KL
    Leon, A
    Viau, AT
    Pilon, D
    Nucci, M
    Shorr, GL
    ARTIFICIAL CELLS BLOOD SUBSTITUTES AND IMMOBILIZATION BIOTECHNOLOGY, 1996, 24 (06): : 655 - 683
  • [26] Comparative studies of polyethylene glycol-modified liposomes prepared using different PEG-modification methods
    Nakamura, Koji
    Yamashita, Keiko
    Itoh, Yuki
    Yoshino, Keisuke
    Nozawa, Shigenori
    Kasukawa, Hiroaki
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2012, 1818 (11): : 2801 - 2807
  • [27] Comparative study on the transition characteristic of poly (vinyl alcohol) (PVA) modified with polyethylene glycol (PEG) by chemical bonding and physical blending methods.
    Na, Y
    Zhang, M
    Niu, YM
    Jiang, ZH
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U369 - U369
  • [28] EFFECT OF FROZEN STORAGE ON POLYETHYLENE-GLYCOL MODIFIED BOVINE HEMOGLOBIN
    BRADLEY, R
    SLOSHBERG, S
    NHO, K
    CZUBA, B
    SHORR, RGL
    FASEB JOURNAL, 1994, 8 (04): : A41 - A41
  • [29] Effects of different linkers and molecular weight of polyethylene glycol (PEG) on the pharmacokinetics, pharmacodynamics and immunogenicity of arginine deiminase
    Holtsberg, FW
    Ensor, CM
    Bomalaski, JS
    Clark, MA
    MOLECULAR BIOLOGY OF THE CELL, 2001, 12 : 241A - 241A
  • [30] Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG
    Kozma, Gergely Tibor
    Meszaros, Tamas
    Berenyi, Petra
    Facsko, Reka
    Patko, Zsofia
    Olah, Csaba Zs.
    Nagy, Adrienne
    Fueloep, Tamas Gyula
    Glatter, Kathryn Anne
    Radovits, Tamas
    Merkely, Bela
    Szebeni, Janos
    VACCINE, 2023, 41 (31) : 4561 - 4570